ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martini, N.
Right arrow Articles by Rigas, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martini, N.
Right arrow Articles by Rigas, J. R.

The Annals of Thoracic Surgery, Vol 55, 1365-1373, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan- Kettering experience with 136 patients

N Martini, MG Kris, BJ Flehinger, RJ Gralla, MS Bains, ME Burt, R Heelan, PM McCormack, KM Pisters and JR Rigas
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.

From 1984 to 1991, 136 patients with histologically confirmed non-small cell lung cancer and stage IIIa (N2) disease received two to three cycles of MVP (mitomycin + vindesine or vinblastine + high-dose cisplatin) chemotherapy. All patients had clinical N2 disease, defined as bulky mediastinal lymph node metastases or multiple levels of lymph node involvement in the ipsilateral mediastinum or subcarinal space on chest roentgenograms, computed tomographic scans, or mediastinoscopy. The overall major response rate to chemotherapy was 77% (105/136). Thirteen patients had a complete response and 92 patients had a partial but major response (> 50%). The overall complete resection rate was 65% (89/136) with a complete resection rate of 78% (82/105) in patients with a major response to chemotherapy. There was no histologic evidence of tumor in the resected specimens of 19 patients. The overall survival was 28% at 3 years and 17% at 5 years (median, 19 months). For patients who had complete resection, the median survival was 27 months and the 3- year and 5-year survivals were 41% and 26%, respectively. There were seven treatment-related deaths, five of which were postoperative deaths. To date, 33 patients, all of whom had complete resection, have had no recurrence after treatment. These results demonstrate that (1) preoperative chemotherapy with MVP produces high response rates in stage IIIa (N2) disease, (2) high complete resection rates occur after response to chemotherapy, and (3) survival is longest in patients who have a complete resection after major response to chemotherapy.


This article has been cited by other articles:


Home page
 JCOHome page
P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al.
Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901
J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens
Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 243S - 265S.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. L. Uy, G. Darling, W. Xu, Q.-L. Yi, M. De Perrot, A. F. Pierre, T. K. Waddell, M. R. Johnston, A. Bezjak, F. A. Shepherd, et al.
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 188 - 193.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. G. Azzoli, M. G. Kris, and D. G. Pfister
Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed
J Natl Cancer Inst, June 6, 2007; 99(11): 828 - 829.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. P. Petersen, D. Pham, E. M. Toloza, W. R. Burfeind, D. H. Harpole Jr, S. I. Hanish, and T. A. D'Amico
Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer.
Ann. Thorac. Surg., July 1, 2006; 82(1): 214 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S.-i. Takeda, H. Maeda, T. Okada, T. Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, and M. Ohta
Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 184 - 189.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas
One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
E. Pezzetta, R. Stupp, A. Zouhair, L. Guillou, P. Taffe, C. von Briel, T. Krueger, and H.-B. Ris
Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC
Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1092 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. L. Port, R. J. Korst, P. C. Lee, M. A. Levin, D. E. Becker, R. Keresztes, and N. K. Altorki
Surgical Resection for Residual N2 Disease After Induction Chemotherapy
Ann. Thorac. Surg., May 1, 2005; 79(5): 1686 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al.
Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Lorent, P. De Leyn, Y. Lievens, E. Verbeken, K. Nackaerts, C. Dooms, D. Van Raemdonck, B. Anrys, J. Vansteenkiste, and The Leuven Lung Cancer Group
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience
Ann. Onc., November 1, 2004; 15(11): 1645 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, E. Felip, M. Taron, J. Majo, P. Mendez, M. Sanchez-Ronco, C. Queralt, J. J. Sanchez, and J. Maestre
Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery
Clin. Cancer Res., June 15, 2004; 10(12): 4215S - 4219S.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Guggino, C. Doddoli, F. Barlesi, P. Acri, B. Chetaille, P. Thomas, R. Giudicelli, and P. Fuentes
Completion pneumonectomy in cancer patients: experience with 55 cases
Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al.
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging
Ann. Onc., March 1, 2004; 15(3): 389 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. L. Port, M. S. Kent, R. J. Korst, R. Keresztes, M. A. Levin, and N. K. Altorki
Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer
Ann. Thorac. Surg., January 1, 2004; 77(1): 254 - 259.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. K. Ferguson
Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. V. Scagliotti, R. Fossati, V. Torri, L. Crino, G. Giaccone, G. Silvano, M. Martelli, M. Clerici, F. Cognetti, and M. Tonato
Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
J Natl Cancer Inst, October 1, 2003; 95(19): 1453 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Betticher, S.-F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, et al.
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial
J. Clin. Oncol., May 1, 2003; 21(9): 1752 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim
Mediastinoscopy in patients with clinical stage I non-small cell lung cancer
Ann. Thorac. Surg., February 1, 2003; 75(2): 364 - 366.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Nagai, R. Tsuchiya, T. Mori, H. Tada, Y. Ichinose, T. Koike, and H. Kato
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)
J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 254 - 260.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S.G. Spiro
Surgery for nonsmall cell lung cancer: can improvements be made?
Eur. Respir. J., January 1, 2003; 21(39_suppl): 52S - 56s.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim
Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer
Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 695 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Cyjon, M. Nili, G. Fink, M. R. Kramer, E. Fenig, J. Sandbank, A. Sulkes, and E. Rakowsky
Advanced non-small cell lung cancer: induction chemotherapy and chemoradiation before operation
Ann. Thorac. Surg., August 1, 2002; 74(2): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Raja, T. El-Hefnawy, L. A. Kelly, M. L. Chestney, J. D. Luketich, and T. E. Godfrey
Temperature-controlled Primer Limit for Multiplexing of Rapid, Quantitative Reverse Transcription-PCR Assays: Application to Intraoperative Cancer Diagnostics
Clin. Chem., August 1, 2002; 48(8): 1329 - 1337.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Martin, R. J. Ginsberg, E. S. Venkatraman, M. S. Bains, R. J. Downey, R. J. Korst, M. G. Kris, and V. W. Rusch
Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 15, 2002; 20(8): 1989 - 1995.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.A. Verschakelen, J. Bogaert, and W. De Wever
Computed tomography in staging for lung cancer
Eur. Respir. J., February 1, 2002; 19(35_suppl): 40S - 48s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.F. Vansteenkiste
Imaging in lung cancer: positron emission tomography scan
Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Deslauriers
Current surgical treatment of nonsmall cell lung cancer 2001
Eur. Respir. J., February 1, 2002; 19(35_suppl): 61S - 70s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. F. Esnaola, S. N. Lazarides, S. J. Mentzer, and K. M. Kuntz
Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 1, 2002; 20(1): 263 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Akhurst, R. J. Downey, M. S. Ginsberg, M. Gonen, M. Bains, R. Korst, R. J. Ginsberg, V. W. Rusch, and S. M. Larson
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer
Ann. Thorac. Surg., January 1, 2002; 73(1): 259 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
L. Voltolini, L. Luzzi, C. Ghiribelli, P. Paladini, M. Di Bisceglie, and G. Gotti
Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy
Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1106 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. Martin, R. J. Ginsberg, A. Abolhoda, M. S. Bains, R. J. Downey, R. J. Korst, T. L. Weigel, M. G. Kris, E. S. Venkatraman, and V. W. Rusch
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy
Ann. Thorac. Surg., October 1, 2001; 72(4): 1149 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J.W. A. Oosterhuis, P. H.M.H. Theunissen, and E. C.M. Bollen
Improved pre-operative mediastinal staging in non-small-cell lung cancer by serial sectioning and immunohistochemical staining of lymph-node biopsies
Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 335 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Doddoli, P. Thomas, X. Thirion, Y. Seree, R. Giudicelli, and P. Fuentes
Postoperative complications in relation with induction therapy for lung cancer
Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 385 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S. Margaritora, A. Cesario, D. Galetta, A. D'Andrilli, G. Macis, G. Mantini, L. Trodella, and P. Granone
Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging?
Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 894 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.F. Vansteenkiste and S.G. Stroobants
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
Eur. Respir. J., April 1, 2001; 17(4): 802 - 820.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Bueno, W. G. Richards, S. J. Swanson, M. T. Jaklitsch, J. M. Lukanich, S. J. Mentzer, and D. J. Sugarbaker
Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival
Ann. Thorac. Surg., December 1, 2000; 70(6): 1826 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Mateu-Navarro, R. Rami-Porta, R. Bastus-Piulats, L. Cirera-Nogueras, and G. Gonzalez-Pont
Remediastinoscopy after induction chemotherapy in non-small cell lung cancer
Ann. Thorac. Surg., August 1, 2000; 70(2): 391 - 395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Van Zandwijk, E. F. Smit, G. W. P. Kramer, F. Schramel, S. Gans, J. Festen, A. Termeer, N. J. J. Schlosser, C. Debruyne, D. Curran, et al.
Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non-Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
J. Clin. Oncol., July 14, 2000; 18(14): 2658 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Okada, N. Tsubota, M. Yoshimura, Y. Miyamoto, and H. Matsuoka
Induction Therapy for Non-small Cell Lung Cancer With Involved Mediastinal Nodes in Multiple Stations
Chest, July 1, 2000; 118(1): 123 - 128.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. Yamamoto, H. Tada, A. Kishi, and T. Tojo
Effects of preoperative chemotherapy and radiation therapy on human bronchial blood flow
J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 939 - 945.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. M.W. Pisters, R. J. Ginsberg, D. J. Giroux, J. B. Putnam Jr, M. G. Kris, D. H. Johnson, J. R. Roberts, J. Mault, J. J. Crowley, and P. A. Bunn Jr
INDUCTION CHEMOTHERAPY BEFORE SURGERY FOR EARLY-STAGE LUNG CANCER: A NOVEL APPROACH
J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 429 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson
Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2000; 6(3): 868 - 873.
[Abstract] [Full Text]

Home page
 ChestHome page
G. M. Strauss
Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer*
Chest, December 1, 1999; 116(suppl_3): 509S - 516S.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Naruke, R. Tsuchiya, H. Kondo, H. Nakayama, and H. Asamura
Lymph node sampling in lung cancer: how should it be done?
Eur. J. Cardiothorac. Surg., September 1, 1999; 16(suppl_1): S17 - S24.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Downey, N. Martini, V. W. Rusch, M. S. Bains, R. J. Korst, and R. J. Ginsberg
Extent of chest wall invasion and survival in patients with lung cancer
Ann. Thorac. Surg., July 1, 1999; 68(1): 188 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Suzuki, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, and Y. Nishiwaki
THE PROGNOSIS OF SURGICALLY RESECTED N2 NON-SMALL CELL LUNGCANCER: THE IMPORTANCE OF CLINICAL N STATUS
J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 145 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. De Leyn, J. Vansteenkiste, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut
Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy
Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 608 - 614.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. A. Rendina, F. Venuta, T. D. Giacomo, A. M. Ciccone, G. Ruvolo, G. F. Coloni, C. Ricci, and S. G. A. Patterson
INDUCTION CHEMOTHERAPY FOR T4 CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER
J. Thorac. Cardiovasc. Surg., February 1, 1999; 117(2): 225 - 233.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. S. Leong, C. M. Rocha Lima, C. A. Sherman, and M. R. Green
The 1997 International Staging System for Non-Small Cell Lung Cancer: Have All the Issues Been Addressed?
Chest, January 1, 1999; 115(1): 242 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts
Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review
Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Nakanishi, T. Osaki, K. Nakanishi, I. Yoshino, T. Yoshimatsu, H. Watanabe, H. Nakata, and K. Yasumoto
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Ann. Thorac. Surg., August 1, 1997; 64(2): 342 - 348.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
J. D. Lee and R. J. Ginsberg
Lung Cancer Staging: The Value of Ipsilateral Scalene Lymph Node Biopsy Performed at Mediastinoscopy
Ann. Thorac. Surg., August 1, 1996; 62(2): 338 - 341.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
M. J. Edelman, D. R. Gandara, M. Roach III, and J. R. Benfield
Multimodality Therapy in Stage III Non-Small Cell Lung Cancer
Ann. Thorac. Surg., May 1, 1996; 61(5): 1564 - 1572.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. J. Mathisen, J. C. Wain, C. Wright, N. Choi, R. Carey, A. Hilgenberg, M. Grossbard, T. Lynch, and H. Grillo
ASSESSMENT OF PREOPERATIVE ACCELERATED RADIOTHERAPY AND CHEMOTHERAPY IN STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER
J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 123 - 133.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. J. Sugarbaker, J. Herndon, L. J. Kohman, M. J. Krasna, M. R. Green, t. C. a. L. G. B T. S. Group, and S. b. V. Rusch
Results of cancer and leukemia group B protocol 8935A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung can